January 10th 2025
Barinthus Bio’s Phase 2b trial shows VTP-300’s potential to achieve functional cures for chronic hepatitis B, with promising HBsAg loss, safety, and durable immune responses.
Advancing Viral Disease Treatment of Recurrent Genital Herpes, Hepatitis B and D Viruses
May 2nd 2024Health care has an unmet need for the treatment of herpesviruses, hepatitis B, and hepatitis D, which would enhance patient outcomes. What should be done, and what challenges do companies that are trying to develop treatments face?